Interacciones de Tabaco y tabaquismo

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3) ] . (etiqueta de Abrocitinib, Advertencia en recuadro)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. (etiqueta de Baricitinib, Advertencia en recuadro)

Instruct the patient the avoid fire, flame, and smoking during and immediately following application. (etiqueta de Calcipotriol, Advertencias y precauciones)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. (etiqueta de Desogestrel y etinilestradiol, Advertencia en recuadro)

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. (etiqueta de Diacetato de etinodiol y etinilestradiol, Advertencia en recuadro)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (etiqueta de Drospirenona y etinilestradiol, Advertencia en recuadro)

Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. (etiqueta de Econazol, Advertencias y precauciones)

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). (etiqueta de Erlotinib, Interacciones medicamentosas)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (etiqueta de Estradiol y dienogest, Advertencia en recuadro)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. (etiqueta de Etonogestrel y etinilestradiol, Advertencia en recuadro)

Therefore, patients being treated with phenelzine sulfate should avoid high protein food that has undergone protein breakdown by aging, fermentation, pickling, smoking, or bacterial contamination. (etiqueta de Fenelzina, Contraindicaciones)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. (etiqueta de Levonorgestrel y etinilestradiol, Advertencia en recuadro)

Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. (etiqueta de Nitroprusiato, Contraindicaciones)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI |GTE 30 kg/m2 • Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. (etiqueta de Norelgestromina y etinilestradiol, Advertencia en recuadro)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. (etiqueta de Noretisterona y etinilestradiol, Advertencia en recuadro)

WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. ● Mono-Linyah is contraindicated in women over 35 years old who smoke. (etiqueta de Norgestimato y etinilestradiol, Advertencia en recuadro)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (etiqueta de Norgestrel y etinilestradiol, Advertencia en recuadro)

Patients who are current or past smokers are at additional increased risk. (etiqueta de Tofacitinib, Advertencia en recuadro)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (etiqueta de Upadacitinib, Advertencia en recuadro)

In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with CHANTIX compared to placebo. (etiqueta de Vareniclina, Advertencias y precauciones)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (etiqueta de Abacavir, Advertencias y precauciones)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (etiqueta de Abacavir y lamivudina, Advertencias y precauciones)

When receiving intravenous ORENCIA, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods. (etiqueta de Abatacept, Interacciones medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ácido mefenámico, Advertencias y precauciones)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (etiqueta de Adalimumab, Advertencias y precauciones)

…elevations for longer periods Hypothyroidism Liver disease; cirrhosis, acute hepatitis Reduced renal function in infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline… (etiqueta de Aminofilina, Advertencias)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monitoring of blood pressure is recommended in patients who receive the combination of bupropion and nicotine replacement. (etiqueta de Bupropión, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Celecoxib, Advertencias y precauciones)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (etiqueta de Clorazepato, Interacciones medicamentosas)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (etiqueta de Clordiazepóxido, Interacciones medicamentosas)

• Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (etiqueta de Clozapina, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco y misoprostol, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Diflunisal, Advertencias)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving RELPAX. (etiqueta de Eletriptán, Advertencias y precauciones)

Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam (see CLINICAL PHARMACOLOGY ). (etiqueta de Estazolam, Interacciones medicamentosas)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (etiqueta de Estradiol, Advertencias)

Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). (etiqueta de Estradiol y noretisterona, Advertencias y precauciones)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (etiqueta de Estrógenos conjugados, Advertencias)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or VTE (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (etiqueta de Estrógenos conjugados y bazedoxifeno, Advertencias y precauciones)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (etiqueta de Estrógenos esterificados y metiltestosterona, Advertencias)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Etodolaco, Advertencias)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Fenoprofeno, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (etiqueta de Flurbiprofeno, Advertencias y precauciones)

In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered. (etiqueta de Flutamida, Advertencias)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (etiqueta de Fluticasona, Advertencias y precauciones)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (etiqueta de Fluvoxamina, Advertencias y precauciones)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan succinate. (etiqueta de Frovatriptán, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Hidrocodona e ibuprofeno, Advertencias)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno y famotidina, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Indometacina, Advertencias y precauciones)

In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. (etiqueta de Insulina regular (humana), Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ketoprofeno, Advertencias)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ketorolaco, Advertencias y precauciones)

Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). (etiqueta de Lenalidomida, Advertencias y precauciones)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (etiqueta de Medroxiprogesterona, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Meloxicam, Advertencias y precauciones)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (etiqueta de Metilergometrina, Advertencias)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Nabumetona, Advertencias)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno y esomeprazol, Advertencias y precauciones)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving naratriptan tablets. (etiqueta de Naratriptán, Advertencias y precauciones)

WARNINGS Cigarette smoking increases the risk of serious cardiovascular disease. (etiqueta de Noretisterona, Advertencias)

This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. (etiqueta de Olanzapina, Interacciones medicamentosas)

This results in a mean increase in olanzapine C max following fluvoxamine administration of 54% in female nonsmokers and 77% in male smokers. (etiqueta de Olanzapina y fluoxetina, Interacciones medicamentosas)

The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (etiqueta de Omalizumab, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Oxaprozina, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Paracetamol e ibuprofeno, Advertencias y precauciones)

Tobacco Smoking tobacco could enhance the metabolic clearance rate of pentazocine reducing the clinical effectiveness of a standard dose of pentazocine. (etiqueta de Pentazocina y naloxona, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Piroxicam, Advertencias y precauciones)

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (etiqueta de Pomalidomida, Advertencias y precauciones)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (etiqueta de Propafenona, Advertencias y precauciones)

CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy [see Clinical Pharmacology ( 12.7 )] . (etiqueta de Propranolol, Interacciones medicamentosas)

Cigarette Smoking (CYP1A2 Inducer) In healthy male heavy smokers, the mean quinine AUC following a single 600 mg dose was 44% lower, the mean C max was 18% lower, and the elimination half-life was shorter (7.5 hours versus 12 hours) than in their non-smoking counterparts. (etiqueta de Quinina, Interacciones medicamentosas)

The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking [see Clinical Studies ( 14.5 )] . (etiqueta de Raloxifeno, Advertencias y precauciones)

Pharmacokinetic Interactions with Adempas Smoking: Plasma concentrations in smokers are reduced by 50% to 60% compared to nonsmokers. (etiqueta de Riociguat, Interacciones medicamentosas)

In this study, current or past smokers had an additional increased risk of overall malignancies. (etiqueta de Ritlecitinib, Advertencias y precauciones)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (etiqueta de Rizatriptán, Advertencias y precauciones)

Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking hormone replacement therapy [ see Clinical Pharmacology ( 12.3 ) ]. (etiqueta de Ropinirol, Interacciones medicamentosas)

Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (etiqueta de Ruxolitinib, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Salsalato, Advertencias)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Sulindaco, Advertencias)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving IMITREX tablets. (etiqueta de Sumatriptán, Advertencias y precauciones)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Cessation of Smoking: Drug Interactions: Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (etiqueta de Teofilina, Advertencias)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Tolmetina, Advertencias)

…contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan,… (etiqueta de Warfarina, Interacciones medicamentosas)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving zolmitriptan. (etiqueta de Zolmitriptán, Advertencias y precauciones)

This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age. (etiqueta de Ácido tranexámico, Advertencias y precauciones)

Tobacco and other medications, have not confirmed these findings. (etiqueta de Clordiazepóxido y clidinio, Interacciones medicamentosas)

Ask a doctor before use if you have chronic cough that lasts such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. (etiqueta de Dextrometorfano, Advertencias)

Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (etiqueta de Dihidroergotamina, Interacciones medicamentosas)

Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (etiqueta de Ergotamina y cafeína, Interacciones medicamentosas)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (etiqueta de Heparina, Interacciones medicamentosas)

All patients had a history of heavy smoking [see Adverse Reactions (6.1) ] . (etiqueta de Infliximab, Advertencias y precauciones)

Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. (etiqueta de Naltrexona y bupropión, Advertencias y precauciones)

Quinidine's pharmacokinetics are also unaffected by cigarette smoking. (etiqueta de Quinidina, Interacciones medicamentosas)